close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

26.20 +0.32 (+1.26%)
Streaming Delayed Price Updated: 11:54 AM EST, Nov 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
38 39 Next >
News headline image
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.’s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)
From Berger Montague
Via GlobeNewswire
News headline image
Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
From Pfizer Inc.
Via Business Wire
News headline image
U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
News headline image
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
News headline image
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:PFE),(NYSE:GSK),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer Declares First-Quarter 2025 Dividend
From Pfizer Inc
Via Business Wire
News headline image
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
From FN Media Group LLC
Via GlobeNewswire
News headline image
Pfizer’s IBRANCE® in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer Invites Public to View and Listen to Webcast of December 17 Conference Call with Analysts to Provide Full-Year 2025 Financial Guidance
From Pfizer Inc.
Via Business Wire
News headline image
Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
From Arvinas Inc.
Via GlobeNewswire
News headline image
Pfizer Showcases Scientific Leadership in Breast Cancer and Blood Disorders Across More than 100 Presentations at ASH and SABCS
From Pfizer Inc.
Via Business Wire
News headline image
Advocating for Justice: Supporting Individuals in the Depo-Provera Litigation
Via Get News
Topics Lawsuit
News headline image
Pfizer Announces New Chief Scientific Officer and President, Research & Development
From Pfizer Inc.
Via Business Wire
News headline image
European Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
News headline image
AWKO Files Lawsuit on Behalf of Sickle Cell Patient Against Pfizer’s Subsidiary
San Francisco, California - Trebor Hardiman, a sickle cell patient from California, has filed a lawsuit against Pfizer’s wholly owned subsidiary Global Blood 
Via Law Firm Newswire
Topics Lawsuit
News headline image
Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance
From Pfizer Inc.
Via Business Wire
News headline image
Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older
From Pfizer Inc.
Via Business Wire
News headline image
U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease
From Pfizer Inc.
Via Business Wire
News headline image
Tim Buckley Elected to Pfizer’s Board of Directors
From Pfizer Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
38 39 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today